Elekta

Elekta A leader in precision radiation therapy, we are committed to ensuring every patient has access to the best cancer care possible.

We collaborate with customers to meet evolving patient needs, improve outcomes and bring hope to those dealing with cancer. At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a ce

ntury to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. This includes our investment in making our cutting-edge solutions broadly available to the millions of people around the world with limited access to cancer care. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in 120 countries and listed on Nasdaq Stockholm.

23/06/2026

This International Women in Engineering Day, we celebrate the women driving safe, life changing innovation.

🔍 As a Software Verification Engineer, Elsa ensures Leksell GammaPlan performs safely and reliably. From reviewing code to hands on testing in the lab, she works to catch edge cases before they ever reach clinicians.

18/06/2026

Thanks to everyone who joined us for Elekta’s Capital Markets Day yesterday in Stockholm.

Together with our CEO Jakob Just-Bomholt, CFO Klara Eiritz, and parts of the leadership team, we shared how we are planning to strengthen profitability and drive long-term growth in the coming years through focused innovation and improved ex*****on.

Watch the webcast and see the presentation here: https://bit.ly/3QMlkMU

Today we announced Elekta’s new mid-term financial targets and a more detailed outlook for FY 2026/27 ahead of our Capit...
17/06/2026

Today we announced Elekta’s new mid-term financial targets and a more detailed outlook for FY 2026/27 ahead of our Capital Markets Day in Stockholm.

👉 Read more in the press release: https://bit.ly/4eqC3Nx

As adaptive radiotherapy continues to move into routine clinical practice, Health Canada’s clearance of Elekta Evo with ...
15/06/2026

As adaptive radiotherapy continues to move into routine clinical practice, Health Canada’s clearance of Elekta Evo with Iris and the Online Adaptive solution marks another important step in that transition.

Ardie Ermers, Head of Region Americas, says:

“This milestone supports the ongoing shift toward making adaptive radiotherapy part of routine care in Canada. It enables clinicians to personalize treatment in real time and improve precision in cancer care. Canada plays an important role in advancing innovation, and this approval also supports collaboration across the oncology community, particularly as we look ahead to AAPM | COMP Joint Scientific Meeting in Vancouver, where adaptive radiotherapy will be a key focus."

It's been a delight to catch up with customers and long time friends who share a profound interest in SRS and SBRT at ....
03/06/2026

It's been a delight to catch up with customers and long time friends who share a profound interest in SRS and SBRT at . Thanks to all who and visited our booth, lunch symposium and demos.

Today, we present our Q4 & full year results. It's a strong finish to the year with improved profitability and our stron...
28/05/2026

Today, we present our Q4 & full year results. It's a strong finish to the year with improved profitability and our strongest cash flow in five years (SEK 1,392 M). With our new operating model in place, we’re focused on near-term profitability and mid-term innovation driven growth. More to come at our Capital Markets Day on June 17. 👉 Read more: https://bit.ly/4dNBblH

21/05/2026

Attending in Sydney? Join us at ICC Sydney, May 31–June 3, to explore the latest advances in stereotactic radiotherapy. Stop by booth 3 to connect with our experts and experience demos of the new AVM workflow with Leksell Gamma Knife.

Save your spot to our Lunch Symposium to learn how innovation is expanding treatment possibilities and improving patient access. 👉 https://bit.ly/3RRyng4

20/05/2026

Highlights from ! ☕️

If you missed our Coffee & Connect sessions at the booth, here are a few key insights and perspectives shared by Prof. Dr Chian Gani, Dr. Matthias Lampe, Dr. Hui Khee Looe and Dr. Erwin Wiegman – covering innovation, clinical experience and the future of radiotherapy.

New findings in glioblastoma show how MR‑guided adaptive radiotherapy can reduce treatment volumes by 40% while maintain...
19/05/2026

New findings in glioblastoma show how MR‑guided adaptive radiotherapy can reduce treatment volumes by 40% while maintaining outcomes and a 4% marginal failure vs 11% historically. A step forward in delivering precise care and helping protect healthy brain tissue.

👉 Read the full study in The Lancet Oncology: https://bit.ly/4tLKIzT

*Study by Detsky et al., UNITED trial investigators at Sunnybrook Health Sciences Centre.

A heartfelt thank you to everyone, both near and far, who spent time with us at . We are grateful for the opportunity t...
18/05/2026

A heartfelt thank you to everyone, both near and far, who spent time with us at . We are grateful for the opportunity to connect in person and look forward to seeing you next year in Milan, Italy!

Adress

Hagaplan 4
Stockholm
10393

Telefon

+46858725400

Webbplats

Aviseringar

Var den första att veta och låt oss skicka ett mail när Elekta postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Affären

Skicka ett meddelande till Elekta:

Genvägar

Dela

Typ